Navigation Links
Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Date:3/20/2011

oma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone to prevent the binding of iron and perpetuation of superoxide production--both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory diffuse large lymphoma without unacceptable rates of cardiotoxicity.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory diffuse large NHL and/or other tumors as determined by the FDA and/or the EMA, whether alone or in combination with rituximab, that if CTI conducts an additional clinical trial, it may not demonstrate the safety and effecti
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Northwest Biotherapeutics Addresses Recent Market Activity
2. MBL Signs Non-Exclusive License With Envoy Therapeutics for Access to RIP-Chip Technology
3. FDA Provides Guidance for Design of Cell Therapeutics Pixantrone Pivotal Trial
4. Reportlinker Adds Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017
5. Cell Therapeutics, Inc. (CTI) to Present at Bio Europe Spring 2011
6. Talecris Biotherapeutics Announces Record Date for 2011 Annual Meeting of Shareholders
7. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
8. MDAs Augies Quest Expands Testing of Potential ALS Therapeutics With New $2 Million Grant to ALS TDI
9. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
10. Pearl Therapeutics Appoints Charles (Chuck) Bramlage President and Chief Executive Officer
11. Talecris Biotherapeutics Announces Fourth Quarter and Full Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... 2014 Lawrence Livermore National ... (WIB) and Las Positas College (LPC) recently established ... and hands-on training for veterans, officials recently announced. ... Las Positas is designed to help veterans ... technician careers, and establishes a pipeline of qualified ...
(Date:7/21/2014)... a chain of carbon atoms can turn it from ... University scientists. , Stretching the material known as carbyne ... by just 3 percent can begin to change its ... mechanically activated nanoscale electronics and optics. , The finding ... appears in the American Chemical Society journal Nano ...
(Date:7/21/2014)... EUGENE, Ore. (July 21, 2014) The yield ... of Oregon have developed a low-energy, solution-based mineral substitution ... that could find use in electronics and alternative energy ... on the cover of the July 21 issue of ... most citations of research in the inorganic and nuclear ...
(Date:7/21/2014)... York , July 21, 2014 ... on Global & USA ... Trends, and Forecasts ResearchMoz presents this ... Biomaker Market   to 2018 (Identification, Technologies, Market Analysis, ... Trends, and Pipeline Analysis. GLOBAL & ...
Breaking Biology Technology:Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3Carbyne morphs when stretched 2Carbyne morphs when stretched 3Oregon chemists eye improved thin films with metal substitution 2Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 2Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 3Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 4Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 5Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 6
... Oncology Biomarkers, FREMONT, Calif., Feb. 6 ... high-value molecular diagnostics company, today announced,the renewal ... University,on the development of novel biomarkers that ... monitoring of prevalent cancers, including,ovarian, breast and ...
... BRL ) today announced that its subsidiary, Barr ... Co., Inc.,s Fosamax(R),(Alendronate Sodium) Tablets, 70 mg after receiving ... The FDA approved the Company,s application on February ... the,earliest to expire of the patents listed with the ...
... 6 Iomai Corporation,(Nasdaq: IOMI ) today announced ... officer, will present at the 10th Annual BIO,CEO & ... 12. Mr. Erck,s,presentation will begin at 2 p.m. Eastern ... Mr. Erck will give an update on corporate ...
Cached Biology Technology:Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests 2Barr Launches Generic Fosamax(R) Tablets, 70 mg 2Barr Launches Generic Fosamax(R) Tablets, 70 mg 3Barr Launches Generic Fosamax(R) Tablets, 70 mg 4Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12 2
(Date:7/22/2014)... showed that mutations in prickle genes cause epilepsy, ... by repeated seizures over time. However, the mechanism ... A new University of Iowa study, published online ... National Academy of Sciences , reveals a novel ... have identified the basic cellular mechanism that goes ...
(Date:7/22/2014)... research in the Journal of Clinical ... signaling and dopamine transporter function are linked ... Parkinsonism and attention deficit hyperactivity disorder (ADHD). ... critical basis for further exploration of how ... contribute to brain disorders" said Michelle Sahai, ...
(Date:7/22/2014)... on July 14, 2014, by lightning from a weather system ... of four fires: Stokes Fire, Gold Hikes Fire, French Creek ... fires are now one larger fire. The fires are burning ... over 243,000 acres in size. The present fire situation ... Public and firefighter safety is the priority on the Carlton ...
Breaking Biology News(10 mins):UI study finds potential genetic link between epilepsy and neurodegenerative disorders 2The dopamine transporter 2The dopamine transporter 3
... from early hominid to dominant species, is the defining ... To chronicle this epic narrative an internationally renowned team, ... University, presents the Wiley-Blackwell Encyclopedia of Human Evolution, a ... history. Over two volumes and 5000 entries ...
... Boston, MA - Some 25 million people in the United ... diseases characterized by often debilitating pain in the joints. Now ... gel that could spell the future for treating these diseases ... the targeted release of medicine at an affected joint, and ...
... crustaceans called copepods rule the world, at least when ... numerous multi-cellular organisms in the seas, copepods are an ... webs. To understand and predict how copepods respond ... how many new copepods are born, but how many ...
Cached Biology News:Injectable gel could spell relief for arthritis sufferers 2Injectable gel could spell relief for arthritis sufferers 3Death -- not just life -- important link in marine ecosystems 2
... Schistosomal glutathione-S-transferase (GST) is commonly used ... in E. coli (1). The GSTTag sequence ... and in some cases the solubility of ... soluble, properly folded form, GSTTag fusion proteins ...
... your samples with eArray and Agilents custom printing. ... own microarray designs that meet your specific biological ... delivery of your arrays in weeks, anywhere in ... creation application tool that enables you to design ...
Acetylcholinesterase (human brain, AChE)...
... 7500ce meets the demands of the routine ... performance from reliable, robust and simple to ... power in the most challenging sample matrices ... equally suited to the toughest analytical challenges ...
Biology Products: